ShivaniAhlawat,MDLauraM.Fayad,MDMuhammadShayanKhan,MDMiriamA.Bredella,MDGordonJ.Harris,PhDD.GarethEvans,MDSaidFarschtschi,MDMichaelA.Jacobs,PhDAvneeshChhabra,MDJohannesM.Salamon,MDRalphWenzel,MDVictorF.Mautner,MDEvaDombi,MDWenliCai,PhDScottR.Plotkin,MD,PhDJaishriO.Blakeley,MDOnbehalfoftheWholeBodyMRICommitteefortheREiNSInternationalCollaborationCorrespondencetoDr.Ahlawat:sahlawa1@jhmi.eduSupplementaldataatNeurology.orgCurrentwhole-bodyMRIapplicationsintheneurofibromatosesNF1,NF2,andschwannomatosisABSTRACTObjectives:TheResponseEvaluationinNeurofibromatosisandSchwannomatosis(REiNS)Inter-nationalCollaborationWhole-BodyMRI(WB-MRI)WorkingGroupreviewedtheexistingliteratureonWB-MRI,anemergingtechnologyforassessingdiseaseinpatientswithneurofibromatosistype1(NF1),neurofibromatosistype2(NF2),andschwannomatosis(SWN),torecommendopti-malimageacquisitionandanalysismethodstoenableWB-MRIasanendpointinNFclinicaltrials.Methods:AsystematicprocesswasusedtoreviewallpublisheddataaboutWB-MRIinNFsyn-dromestoassessdiagnosticaccuracy,feasibilityandreproducibility,anddataaboutspecifictechniquesforassessmentoftumorburden,characterizationofneoplasms,andresponsetotherapy.Results:WB-MRIat1.5Tor3.0Tisfeasibleforimageacquisition.Shorttauinversionrecovery(STIR)sequenceisusedinallinvestigationstodate,suggestingconsensusabouttheutilityofthissequencefordetectionofWBtumorburdeninpeoplewithNF.Thereareinsufficientdatatosupportaconsensusstatementabouttheoptimalimagingplanes(axialvscoronal)or2Dvs3Dapproaches.Functionalimaging,althoughusedinsomeNFstudies,hasnotbeensystematicallyappliedoreval-uated.TherearenocomparativestudiesbetweenregionalvsWB-MRIorevaluationsofWB-MRIreproducibility.Conclusions:WB-MRIisfeasibleforidentifyingtumorsusingboth1.5Tand3.0Tsystems.TheSTIRsequenceisacoresequence.Additionalinvestigationisneededtodefinetheoptimalapproachforvolumetricanalysis,thereproducibilityofWB-MRIinNF,andthediagnosticperfor-manceofWB-MRIvsregionalMRI.Neurology®2016;87(Suppl1):S31–S39GLOSSARYADC5apparentdiffusioncoefficient;DWI5diffusion-weightedimaging;FDG5fluorodeoxyglucose;MPR5multiplanarreformation;NF15neurofibromatosistype1;NF25neurofibromatosistype2;PNST5peripheralnervesheathtumors;REiNS5ResponseEvaluationinNeurofibromatosisandSchwannomatosis;SNR5signaltonoiseratio;STIR5shorttauinversionrecovery;SWN5schwannomatosis;WB-MRI5whole-bodyMRI.Whole-bodyMRI(WB-MRI)allowsimagingofalargevolumeofthebodyinasingleimageacquisitionsession.Ithasbeenextensivelyinvestigatedforthedetectionandstagingofvisceralandosseoustumors1–6andiswell-suitedtotumorsyndromesincludingneurofibromatosistype1(NF1),neurofibromatosistype2(NF2),andschwannomatosis(SWN),7–9asthesepatientsoftenhaveahighburdenoftumorsaswellaslargetumorsthatcrossanatomicplanes(figure).WB-MRIhasbeenusedtoevaluatetumorburdenandtocharacterizeneoplasmsinpatientswithNFsyndromes10–23andisbeingusedinsomeclinicaltrialstoevaluateresponsetotherapy(NCT01207687).AuniformimageacquisitionprotocolandinterpretationmethodwouldenableWB-MRItobeusedasakeyendpointtoassesstumortreatmentresponseinmulticenterFromTheRussellH.MorganDepartmentofRadiologyandRadiologicalScience(S.A.,L.M.F.,M.A.J.),SidneyKimmelComprehensiveCancerCenter(M.A.J.),andDepartmentofNeurology(J.O.B.),JohnsHopkinsUniversity,Baltimore,MD;KhyberMedicalCollege(M.S.K.),Peshawar,Pakistan;DepartmentofRadiology(M.A.B.,G.J.H.,W.C.),MassachusettsGeneralHospitalandHarvardMedicalSchool,Boston;GenomicMedicine(D.G.E.),ManchesterAcademicHealthScienceCentre,TheUniversityofManchester,UK;DepartmentofNeurology(S.F.,V.F.M.),UniversityMedicalCenterHamburg-Eppendorf,Hamburg,Germany;Radiology&OrthopedicSurgery(A.C.),UTSouthwesternMedicalCenter,Dallas,TX;DepartmentofDiagnosticandInterventionalRadiology(J.M.S.),UniversityHospitalHamburg-Eppendorf;RadiologicalPracticeAltona(R.W.),Hamburg,Germany;PediatricOncologyBranch(E.D.),NationalCancerInstitute,Bethesda,MD;andDepartmentofNeurologyandCancerCenter(S.R.P.),MassachusettsGeneralHospital,Boston.REiNSInternationalCollaborationmembersarelistedontheNeurology®WebsiteatNeurology.org.GotoNeurology.orgforfulldisclosures.Fundinginformationanddisclosuresdeemedrelevantbytheauthors,ifany,areprovidedattheendofthearticle.©2016AmericanAcademyofNeurologyS31ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.clinicaltrialsforNF-associatedperipheralnervesheathtumors(PNST).However,thusfar,vari-ableapproacheshavebeenusedforWB-MRIacquisitionandimageanalysisinNF.TheWB-MRIWorkingGroupwasformedaspartoftheResponseEvaluationinNeurofi-bromatosisandSchwannomatosis(REiNS)InternationalCollaborationtogeneratecon-sensusrecommendationsandidentifypriorityareasforfutureresearchregardingWB-MRIasappliedtoNFclinicaltrials.TheworkinggroupreviewedtheexistingliteratureontheuseofWB-MRIinpatientswithNF1,NF2,andSWNtoevaluatedifferencesinimageacquisition(includingmagnetstrengths,imag-ingplanes,and2Dvs3Dapproaches);assessthefeasibility,reproducibility,anddiagnosticaccuracyofWB-MRIinpeoplewithNF;andevaluatethebenefitsoffunctionalMRItechniques,suchasdiffusion-weightedimaging(DWI)withquantitativeapparentdiffusioncoefficient(ADC)mapsandcontrast-enhancedimagingforNF-associatedPNST.WeusedthisinformationtorecommendbestpracticesforWB-MRIforuseinNFclinicaltrialsandtoestablishresearchprioritiesforfuturestudies.METHODSAcomputer-aidedsearchofPubMed/MEDLINEfrominceptiontoMay2015wasconductedtofindrelevantEnglishlanguagepublicationsonWB-MRIandNFsyndromes.Toexpandoursearch,bibliographiesofretrievedarticleswerescreenedforadditionalcitations.Asinglereviewer(S.A.)independentlyscreenedtitles,abstracts,fullarticles,andreferencestodetermineeligibilityforinclusion.StudieswereincludediftheyhadaprospectiveorretrospectivestudydesignwithpatientsofanyagewithNF1,NF2,andSWNusingWB-MRIinwhichatleasttheareafromthenecktothepelviswasimaged.Reviewarticles,meta-analyses,abstracts,casereports,orcaseseriesoflessthan10patients,guidelines,orstudiesperformedinanimalswereexcluded.Inclusionofpatientsbasedonwell-establishedclinicalcriteriafortheNFsyndromeswasadequateforselectionofthepatientpop-ulation,giventhatpathologicconfirmationofeachneoplasmisnotfeasible.7–9Allincludedarticleswereanalyzedfordiagnosis(NF1,NF2,andSWN),indextest(WB-MRI),andreferencetest(clinicalcriteriafordiagnosisoftheNFsyndromes).Thefollowinginfor-mationwasextractedfromarticles:authorname,yearofpublica-tion,numberofparticipants,specifictumorsyndrome,magnetstrength(1.5Tvs3.0T),specificWB-MRItechniques(2Dvs3Dimaging,specificimagingsequences,inclusionoffunctionalMRIsequences,contrastadministration),sex,meanagewithSD,quan-tificationofPNSTsize(2Dvsvolumetric),andtypesoftumors(malignantvsbenignPNST).WB-MRIstudieswerealsoclassifiedbyclinicalindicationinto3categories:tumordetection(includingextentofdisease),tumorcharacterization,orresponsetotherapy.RESULTSTheliteraturesearchyielded25articles.Afterfullreviewofthearticles,14studiesmetallinclu-sioncriteria.10–23Twostudieswereexcludedastheydiscussedextratumoralfindings(i.e.,incidentalfind-ingsonWB-MRIinNFormarrowchangesinpatientswithNFtreatedwithimatinibmesylate22,23).Hence,thefinalanalysisincluded12studies.10–21WB-MRIacquisitionprotocols.Table1summarizestheinformationextractedfromtheinvestigationsthatmetinclusioncriteria.Ofthe12publications,11employed1.5Tmagnetstrength10–12,14–21;only1studyused3.0Tmagnet.13Onestudyperformedat3.0Tacquiredvolumetric3Dimageswithisotropicresolutioninthecoronalplaneandgeneratedmulti-planarreformations(MPR)insagittalandaxialplanewithgooddiagnosticquality.13TheremainderoftheWB-MRIinvestigationsutilized2Dacquisitionsinthecoronalplanealone,orinbothcoronalandaxialplanes.AllinvestigationsincludedashorttauinversionFigureWhole-bodyMRIinneurofibromatosis(A)Apersonwithschwannomatosis.(B)Apersonwithneurofibromatosistype1.Inbothim-ages,therangeoffieldofviewisapparentdependingonthetablelengthandthesizeofthepersonbeingimagedandinbothimagesseveraltumorsdistributedacrossanatomicregionscanbeidentified.In(B),someoftheartifactthatcanoccuraffectinginterpretationisapparent.S32Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.recovery(STIR)sequence.Only1trialperformedfunctionalMRIwithquantitativeDWIandADCmaps.13DWItechniqueincluded3bvaluesandwasperformedwithslicethicknessof5mm.13Threeofthe12studiesusedcontrastmaterialasanadjuncttotraditionalWB-MRIfluid-sensitivesequences.11,13,14Onestudyobtainedpostcontrast3Dvolumetricgradientechoimages13whiletheotherstudyobtained2DspinechoT1-weightedimageswithfatsuppression.14In1study,investigatorsfoundcontrasttobeusefulindistinguishingPNSTfromperineuralcysts.13WB-MRIapplications.Withrespecttoimageinterpreta-tionandanalysis,thefollowingaspectswerespecificallyassessed:tumordetection(evaluationofWBtumorburden,includingtumorsize),tumorcharacterization,andtheassessmentoftreatmentresponse(table2).TherearevariedmethodsofWBtumorburdeneval-uation,withrecentstudiesfavoring3Dtumorvolu-metry,ratherthan1Dor2Dlinearmeasurements(suchasResponseEvaluationCriteriainSolidTumors[RECIST]).Fiveofthe12publishedinvestigationsinthisstudyutilizedMedXsoftware(v3.42;SensorSys-tems,Inc.,Sterling,VA),asemi-automatedmethodforsegmentationandmeasurementwithaheuristics-basedalgorithmforvolumetricanalysis,14,15,17,18,21while5ofthe12publicationsusedacomputerized3D-volumetrymethoddevelopedforWB-MRIusingthedynamicthresholdlevelsetmethod.10–12,16,19TherearelimiteddatawithregardstocharacterizationofneoplasmsasbenignormalignantandnodatatodateTable1ImagingparametersforWB-MRIfromNF-relatedinvestigationsfocusedondetectionorcharacterizationofPNSTPublication(seereferences)Technicalconsiderations:magnetstrength(1.5Tvs3T);sequences(2Dvs3D);planeofacquisition(axial,coronal,sagittal)SpecificsequencesContrastmaterial(1/2)FunctionalDWIandADCmapping(1/2)101.5T;2D;coronalSTIR22111.5T;2DaSTIR:slicethickness5–10mm;matrix256–5123256;T1;slicethickness5–10mm;matrix256–51232561;Gadolinium-DTPA(Magnevist,BayerScheringPharmaAG,Germany)2121.5T;2D;coronalSTIR:TR/TE/IR4,190/111/150;echotrainlength25;FOV50cm;matrix3203240;slicethickness10mm;nointerslicegap22133.0T;3D;coronalPreandpostcontrastVIBE:TR/TE0.88/2/43ms;FOV50cm2;matrix2563256;slicethickness2mm;STIR:TR/TE6,640/84ms;FOV50cm2;matrix2563256;slicethickness2mmwithinterpolation1;0.1mmol/kggadodiamidecontrastagent(Magnevist,BayerScheringPharmaAG,Germany)1;TR/TE4,100/70ms;bvalues50,400,800s/mm2;FOV50cm2;slicethickness5mm141.5T;2D;coronalandaxialSTIR:axial;TR/TE3,690ms/106ms;FOV25.7350.0cm;coronal;TR/TE3,110ms/101ms;FOV48cm2;T1WFSpreandpostcontrast:axial;TR/TE91ms/4.76ms;FOV47.9cm20.1mmol/kgor0.2mmol/kgbodyweightgadolinium-DTPA2151.5T;2DaSTIR:slicethickness10mm;nointerslicegap22161.5T;2D;coronalSTIR:TR/TE/IR4,190/111/150;slicethickness10mm;nointerslicegap;FOV50cm2;echotrainlength25;matrix320324022171.5T;2D;axialSTIR:slicethickness10mm22181.5T;2D;axialSTIR:slicethickness10mm22191.5T;2D;coronalSTIR:TR/TE/IR4,190/111/150;slicethickness10mm;nointerslicegap;FOV50cm2;echotrainlength25;matrix320324022201.5T;2D;coronalandaxialAxial:T1(slicethickness6–12mm);T2FS(slicethickness6–12mm);coronal:T1(slicethickness5–10mm);T2FS(slicethickness5–10mm)22211.5T;2D;coronalandaxialT1SE:slicethickness5–10mm;nointerslicegap;STIR;slicethickness5–10mm;nointerslicegap22Abbreviations:ADC5apparentdiffusioncoefficient;DWI5diffusion-weightedimaging;FOV5fieldofview;IR5inversionrecovery;NF5neurofibro-matosis;PNST5peripheralnervesheathtumors;STIR5shorttauinversionrecovery;TE5echotime;TR5repetitiontime;VIBE5T1-weightedsequences(volumeinterpolatedbreath-holdexamination);WB-MRI5whole-bodyMRI.aAplaneofimagingisnotspecified.Neurology87(Suppl1)August16,2016S33ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.Table2SummaryofWB-MRIinvestigationswithrespecttoimageinterpretationfocusedontumordetection(assessmentofwholebodytumorburden),characterization,andtreatmentresponseReferencePatientpopulation,n,sexcomposition(%male),age,yTumordetection(diseaseburden)Conclusion10245totalPNSTweresegmentedusingcomputerized3D-volumetrymethodsdevelopedforreference19InternaltumorburdenisnotaprimarycontributortoQOLbutitdoescorrelatewithSF-36bodilypainscore1193(31NF1withMPNSTand62NF1withoutMPNST),58%,medianage34(range7–67)PNSTweresegmentedusingcomputerized3D-volumetrymethodsdevelopedforreference19HighernumberofinternalPNsandagreaterwhole-bodyPNvolumeareimportantriskfactorsforthedevelopmentofMPNST1219(NF1),52%,meanage38(range19–58)Tumorvolumerange(0.4–1,182.4mL);PNSTweresegmentedusingcomputerized3D-volumetrymethodsdevelopedforreference19NF1patientswithdeeptumorsandtumorswithinthetrunkaremorelikelytohavemetabolicallyavid(SUVmaxgreaterthan2.5)PNST;increasedPNSTsize,location,andplexiformappearancewereassociatedwithincreasedoddsofhavingametabolicallyactivePNST1311(NF2andSWN)23lesions(median3.5cm,range1.0–10.2cm);2/23,cyst;21/23,PNSTWB-MRIwithvolumetricsequencesisfeasiblefordetectionofPNSTinNF;additionofDWIandcontrastenablespotentialforcharacterizationofcystsvstumors;cystslackenhancementandhavehigherADCvalues1431,42%,meanage30.4614.7(range2–63)PNSTweresegmentedusingcomputerized3D-volumetrymethodsdevelopedforreference19AlthoughPET/CThasahighersensitivityonaperlesionbasisforcharacterizationofPNSTasbenignormalignant,additionofWB-MRImaydecreasetheFPrate15201(71withinternalPNST),44%,medianage28.6(range1.7–63.4)VolumetrywasperformedusingMedXsoftware(v3.42;SensorSystems,Sterling,VA),aheuristics-basedsemi-automatedmethodforsegmentationandmeasurement36Whole-bodyPNSTvolumeatthetimeoftheinitialWB-MRIcorrelatedwiththeabsoluterateofPNSTgrowth;newPNSTareinfrequentinpatientswithNF1withPNSTandunlikelyinpatientswithoutPNST16247Totalof1,286PNST(528plexiformand758circumscribedtumors);PNSTvolume,65,423mLin145/247patients;PNSTweresegmentedusingcomputerized3D-volumetrymethodsdevelopedforreference19PatientswithSWNhadthehighestprevalenceofPNST,butpatientswithNF1hadthehighestmediantumorvolume1738withlargeNF1deletionand114age-andsex-matchedNF1patientswithoutlargedeletionInternalPNSTin22/38(58%)deletionand67/114(59%)nondeletionpatients;volumetrywasperformedusingMedXsoftware(v3.42;SensorSystems),aheuristics-basedsemi-automatedmethodforsegmentationandmeasurement36PatientswithNF1withlargedeletionshavehigherinternalPNSTburden1865(37withPNST),46%,mean10.5(range1.7–17.6)73PNST;meanvolume145.5mL(excludedPNST,3cm);volumetrywasperformedusingMedXsoftware(v3.42;SensorSystems),aheuristics-basedsemi-automatedmethodforsegmentationandmeasurement36PNSTcancauseclinicaldeficitinpediatricpatientswithNF11952(NF1:28,NF2:14,SWN:10),48%,meanage42615(SD)(range24–86)398Nervesheathtumors(185plexiformand213discretetumors)wereidentifiedin29patients;manualandsemi-automated3Dsegmentedvolumetryfor25plexiformand25solitaryPNSTwithhighreliabilityaDTlevelsetsemi-automatedsegmentationisreliablerelativetomanualsegmentation2024NF1,29%,meanandmedianage36(range15–59)4/24,Plexiform;20/24,solitary;nomajorproblemstodifferentiatePNSTfromlymphnodes,vessels,orcystsWB-MRIisfeasibleinNF1fordetectionofPNSTandassessmentoftumorburden2139(13NF1withMPNSTand2age-/sex-matchedNF1withoutMPNST),46%VolumetryusingMEDxsoftwareplatform37WB-MRIenablesdetectionofinternalPNSTburdenAbbreviations:ADC5apparentdiffusioncoefficient;DWI5diffusion-weightedimaging;FP5falsepositive;MPNST5malignantperipheralnervesheathtumor;NF15neurofibromatosistype1;NF25neurofibromatosistype2;PN5peripheralnerve;PNST5peripheralnervesheathtumors;QOL5qualityoflife;SF-365ShortForm–36;SWN5schwannomatosis;WB-MRI5whole-bodyMRI.aSegmentedusingcomputerized3D-volumetrymethodsdevelopedforWB-MRIusing(thedynamicthreshold[DT]levelsetmethod).S34Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.forassessmentoftreatmentresponse,althoughsuchanalysisisongoinginaclinicaltrialassessingWB-MRIovertimeinpeoplewithNF2treatedwithbevacizumab(NCT01207687).Thedatafromtables1and2werecriticallyevalu-atedtogenerateknowledgegapsandfuturedirectionsforWB-MRIinvestigationstoprovidetherequiredmetricsforinclusionofWB-MRIasaprimaryend-pointinclinicaltrialsforNF-associatedPNST.PriorityareasidentifiedincludeWB-MRIreproducibilityforanatomicalmeasures,optimalanalysistechniques,andestablishingtheminimalmeaningfulclinicaldifferenceintumorsize(table3).DISCUSSIONWB-MRIprovidescontinuouscover-ageoflesionsthatcrossanatomicalboundariesandthereforecannotbefullyimagedwithlocalizedMRI,asignificantadvantagewhenevaluatingpatientswithNFsyndromeswheretherearefrequentlylargeinfiltra-tivetumors(figure)ormultifocalPNST,whichmaybemissedwithoutWB-MRIassessment.21Inthissetting,WB-MRIallowsassessmentofdifferentialresponsewithinandacrosstumorsovertime.AnadditionaladvantageisthatWB-MRIcanbecompletedwithatypicalscantimeof45–60minutesonboth1.5Tand3.0Tsystemsandusesthesameprotocolsforpatientsofallages,allowingcontinuityacrossandwithinpatientsenrolledinatherapeutictrial.12,13,18Amajorgoalofthisworkwastoidentifycoreas-pectsofWB-MRIapplicationforassessmentofNF-associatedPNSTtoenableinclusionofWB-MRIasaprimaryendpointfortherapeutictrialsofNF-associatedPNST.Therearenocomparativedataavailablewithrespecttomagnetstrength,imageacquisitionplane(axialvscoronal),2Dor3Dacqui-sition,orthevalueoffunctionalimagingandadmin-istrationofcontrastmaterialavailableacrossallavailableinvestigations.However,aftertheanalysesoftheWB-MRIstudiesinpatientswithNFcon-ductedtodate,severalstatementscanbemade:WB-MRIinNFisfeasiblebothat1.5Tor3.0T;itcanbestandardizedacrossmultiplesitesforanatomictumorassessmentinthesettingofaclinicaltrial;both2Dand3Dacquisitionareoperationalforgeneratingtumordata;STIRisacoresequenceforevaluationoftumorburden;andfunctionalsequencessuchasDWIcanbeconsideredinthesettingofWB-MRI.Outsideofthesestatements,theWB-MRIWorkingGroupofREiNSisnotabletomakespecificrecom-mendationsforacquisitionprotocolsatthistimeduetoalackofdata.Forexample,onlyasinglecaseseriesof4patientscomparedanalysisoftumorburdeninpatientswithNF1whounderwentWB-MRIonboth1.5Tand3.0Twithina6-monthperiod.24Thisstudyshowednodifferenceintumorvolumesbetweenthe2magnetstrengths;however,therearenoothercom-parativeanalysesandthisstudyistoosmalltodrawconclusions.Themajorityofstudiescompletedtodateuse1.5Tasthisismorewidelyavailable.Thewideavailabilityof1.5TmagnetsisanadvantageforapplicationofWB-MRItomulticentertrials.How-ever,3.0TWB-MRIhastheoreticaladvantages,suchasincreasedsignaltonoiseratios(SNR),allowingforimproved3DsequencesaswellasallowingforDWIacquisitioninanacceptableimagingtime.Potentialdisadvantagesof3.0TMRIincludeB1fieldinhomo-geneitiesandsusceptibilityartifacts.2,13Workisongo-ingtooptimizethiswithtechnologicaladvancessuchascontinuoustablemotionandimprovedcoils,whichareexpectedtoshortenacquisitionandincreaseSNR.2,25Withrespecttospecificsequences,theSTIRsequence,withitscombinedT1andT2weighting,hasbeenuniformlyusedintheWB-MRIinvestigationsforPNST.Mostpathologicprocesses,includingtu-mors,areproton-richwithresultantprolongedT1andT2relaxationtimesandincreasedsignalintensityonSTIRimages.Inaddition,fatsuppressionismorerobustandhomogeneousoninversionrecoverysequen-cesthanotherfrequencyselectivesequences.Thesefea-turesmaketheSTIRsequencevaluablefordetectionandmeasurementofPNSTandacoresequenceforassessmentofwholebodytumorburdeninNF.How-ever,detectionofotherpathologiesinthevisceraortheskeletalsystemmayrequireadditionalimaging.Regarding2Dand3Dacquisitions,11ofthe12studiesused2Dimagingsequences,10–12,14–21whileon-ly1study(at3.0T)obtainedimageswith3Dvolu-metricsequences.13Thisallowsustosaythatbotharefeasible,buttherearenodatatosuggestadvantagesofoneovertheother.Thereareimportantdifferencesinspatialresolutionbetween2Dand3Dsequences.For2Dsequencesobtainedat1.5T,thein-planeresolutioncanbe0.3–1.5mmandtheslicethicknesscanrangefrom5to10mmwithnointerslicegap.WB-MRIatTable3Futuredirectionsforwhole-bodyMRI(WB-MRI)investigationsinpatientswithneurofibromatosis(NF)Sensitivity,specificity,andreproducibilityofWB-MRIinNF1.Comparativestudyof3.0Tvs1.5Tfortumordetection2.Comparativestudyfor2Dvs3Dacquisitionfortumordetection3.Comparativestudyofaxialvscoronalimagingacquisitionfortumordetection4.ComparativestudyofregionalvsWB-MRIfortumordetection5.TestretestvariabilityandinterobserverperformanceofWB-MRIinNF6.DeterminationoftheminimallymeaningfulclinicalchangeoftumorsizewithWB-MRIBiologiccharacterizationoftumor1.InvestigatefunctionalMRI(diffusion-weightedimaging/apparentdiffusioncoefficientmapping)vsotherimagingmodalitiessuchasfluorodeoxyglucosePETfortumorcharacterizationandassessmentoftreatmentresponse2.Investigatetheaddedvalueofcontrast-enhancedimagingtoWB-MRIprotocolforcharacterizationandassessmentoftreatmentresponseNeurology87(Suppl1)August16,2016S35ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.thisresolutionmaynotbeadequateforthedetectionorcharacterizationofverysmallneoplasmsandPNSTlocatedintheskinandsubcutaneoustissues.3Dsequencesobtainedat3.0Tcanhaveaninterpolatedspatialresolutionof2mmwithslicethicknessof2mmandnointerslicegap.13Both2Dand3Dsequencescanalsobeperformedwithhigherspatialresolution,butatthecostoflongeracquisitiontime.Apotentialadvan-tageof3DsequencesincludesMPRcapabilitiessuchthata3Disotropicdatasetcanbedisplayedinanyimagingplane.However,3Dacquisitionmaynotbeavailableonallscanners,limitingapplicationinmul-ticenterstudies.Forboth2Dand3Dsequences,thereisalackofconsensusregardinganoptimalimagingplane.AlthoughallWB-MRIinvestigationstodatehaveincludedthecoronalplane,nocomparativestudyhasbeenperformedtodeterminetheidealimagingplane.AnadvantageofcoronalimageacquisitionisthatforanatomicsequencessuchasSTIRorT1-weigtedimaging,thereislessrespiratorymotionduetofasterimageacquisition.Ofnote,thecoronalimageacquisitionmaynotbeoptimalforDWI,par-ticularlyintheneckandthoracicregions,duetocar-diacmotion.ThereisalsoalackofdataregardingtheaddedvalueofIVcontrastmaterial.Useofexogenouscon-trastrequiresvenousaccessandhemodynamicmon-itoringduringtheWB-MRIacquisitionthatmayreducefeasibilityandcarriestheadditionalriskofnephrogenicsystemicfibrosisinthesettingofrenalfailure.Newliteraturealsosuggestsarelationshipbetweenrepetitivegadoliniumexposureandhighsig-nalintensityinthebasalganglia,furtherraisingcon-cernaboutexogenouscontrast.26Therearecurrentlyinsufficientdatatoassessthepotentialdiagnosticben-efitvsriskoftheuseofIVcontrastforPNST.Finally,noinvestigationshavebeenperformedtoassesstheaddedvalueofDWIwithADCmapstostandardsequencesinWB-MRIinpatientswithNF.Thisisfeasibleandthepotentialadvantagesincludetheassessmentoftumorbiologyandpossiblytreatmentresponse,theabilitytodistinguishacystfromaneo-plasm,andthecharacterizationofincidentalfindings.Forexample,specificthresholdADCvaluesenabledistinguishingsofttissuemassesfromcystswithhighspecificity(100%),importantwhenquantifyingtumorburden.13,27Similarly,thereislocalizedMRIexperienceusingDWIandADCmappingforPNSTcharacterizationasbenignormalignantwith100%sensitivity(95%confidenceinterval66.4%–100%)and77%specificity.28Thereisalsolimitedexperi-encecomparingWB-MRIwithwholebody18F-flu-orodeoxyglucose(FDG)PET/CTforcharacterizingPNSTasbenignormalignant.14Although18F-FDGPET/CThadhighersensitivity(100%)comparedwithWB-MRI(66.7%)onaperlesionbasis,WB-MRIhadahigherspecificity(97%forWB-MRIvs74.4%for18F-FDGPET/CT)fordetectingmalig-nancy.14WB-MRIinthisparticularinvestigationusedroutineanatomicsequencesonly,14andthusitremainstobedeterminedwhetheradditionofquan-titativefunctionalMRIsequenceswithADCmeas-urementswouldalterthediagnosticaccuracyfordetectionofmalignancy.AlthoughWB-MRIwithfunctionalsequencesfordetectionandcharacterizationofbenignvsmalignantPNSTshowspromise,currentlythesesequencescanbedifficulttoperformuniformlyacrossmultiplesites.Noinvestigationshavebeenpublishedtodateregard-ingtheassessmentoftreatmentresponseinPNSTinNF,butthereareeffortscurrentlyforanalysisofongoingtherapeuticstudieswithpretreatmentandposttreatmentWB-MRI(NCT01207687).ThisstudywillalsoallowassessmentoftheaddedvalueoffunctionalMRIorcontrast-enhancedsequencesforassessingchangesintumorbiologyindependentofchangesintumorsize.WithrespecttoWB-MRIanalysis,thefieldhasrec-ommendedvolumetricmeasurementsoftumorratherthan2Dmeasures.29–31TumorvolumetryispreferredforquantifyingcomplexPNSTsuchasplexiformneu-rofibromasthatcanbelargeandinfiltrativewhereas2Dorlinearmeasurementismorelikelytomisrepre-sentthetruetumordimensionsbyoverestimatingorunderestimatingPNSTsizeandcanbefraughtwithinterobserverandintraobservervariations.32–34Tumorvolumetry,particularlyininfiltrativeplexiformneo-plasmssuchastheonesidentifiedinpatientswithNFsyndromes,hasbecometheoptimalapproachforassessingtumorburden.Inaddition,thecurrentther-apeutictrialsinNFsyndromesusevolumetricanalysisasaprimaryorsecondaryendpoint(NCT01362803,NCT02101736,NCT02096471).Volumetrictumorburdencanbemeasuredmanually,thoughthisistime-consumingandimpracticalforroutineclinicalevalua-tion.Computer-aidedtumorsegmentationofPNSTcanbeperformedonMRIsequencesthatshowcleardistinctionbetweentumorandsurroundingnormaltissue,suchasSTIRorsimilarfluidsensitivesequen-ces.Inonestudycomparingmanualandsemi-automatedtumorvolumetry,computerizedvolumetryusingadynamicthresholdmethodwassuperiortomanualsegmentationtechniques.19Moreover,com-puterizedvolumetrywasreliableandlesslaborinten-sive,whichmadeitmorerepeatablecomparedtomanualsegmentation.19Itisimportanttonotethatreliabilityandrepeatabilitywerecalculatedusingasmallsamplesize19;however,thistechniquehassubse-quentlybeenappliedinlargerstudiesofapproximately250patients.10–12Amulticenterstudycomparingthe2principalsemi-automatedmethodsforreliabilityandS36Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.interpretationtimecomparedwiththemanualtech-niqueinlesiondetectionandchangeinlesionsizeiscurrentlyunderway.AlthoughthereareseveraladvantagestoWB-MRIforNF,therearealsoimportantlimitations.First,forverytallorlargeindividuals,portionsofthebodymaynotbeadequatelyimaged,includingthedistallegs,shoulders,andarms.Adequateimagingofthedistallowerextremitiesisaparticularconcernfor3.0TscannersandmaylimittheuseofWB-MRIiftherearetumorsofinterestintheseregions.Thiscanbead-dressedbyimagingtheupperandlowerbodysepa-rately;however,thisincreasescostandtime.AnadditionalconcernfortumorassessmentwithWB-MRIisthatthelowerlimitoftumorvolumethatcanbeassessedhasnotbeendescribed,anddepend-ingontheWB-MRItechniqueaswellasthetumordistribution,thecutoffvaluemaybevariable.Select-ingthesamePNSTforcontouringconsistentlyoverconsecutivescansiscrucialfordeterminingsizechangeandcanonlybedoneoncomparablequalityimagesets.Similarly,diagnosticperformanceofWB-MRIfortotaltumorburdenestimatesisdepen-dentonthecorrectrepresentationofthebodyontheMRIandneedstobestandardizedacrosssitesandtimepoints.Importantly,WB-MRIcansufferfromvariedimagedistortionsattheperipheryoftheimag-ingfield,whichmayleadtomeasurementerrors.13Givenspatialresolutionlimitationsanddependingonwhatsequencesareapplied,additionaldedicatedMRIsequencessuchasmagneticresonanceneurog-raphymaybenecessarytoprovideimprovedana-tomicandfunctionalcharacterizationofPNST,35evaluatetumorsinandaroundthespinalcord,iden-tifysmalltumorssuchaspheochromocytomas,ordiagnosevascularanomalies.Finally,itisworthnot-ingthattherearesomelimitationstotheanalysispresentedbasedontheverylimitedliteratureonthistopic.Only14investigationsfulfilledsearchcriteria.Ofthese,severalstudieshadoverlappingpatientdataandWB-MRIprotocolsreportedwithseparateend-points.10,16,19ThisfurtherhighlightstheneedforadditionalresearchonWB-MRIperformanceinNFsyndromes(table3).ChoosingstandardizedimageacquisitionandanalysismethodsisessentialforoptimalmulticentercollaborationapplyingWB-MRIasatoolforassess-ingtumorsinNF.WB-MRImayserveaseitherapri-maryorsecondaryendpointinclinicaldrugtrialsthattargetmultipletumorsrequiringsystemicratherthanlocalizedimaging.ThesystematicprocessdevelopedbytheREiNSWB-MRIWorkingGrouphasenabledamulticenterconversationaboutimagingprotocolsandthedevelopmentoffuturecomparativeprojects.TheseresultswillbeusedbythegrouptoidentifythemostappropriateWB-MRIacquisitionandinterpretationmethodsforindividualswithNFsyn-dromesinfutureclinicaltrialsandprioritizeresearchquestionsabouttheoptimaluseofWB-MRIasanendpointmeasureinNFresearch.AUTHORCONTRIBUTIONSS.Ahlawat:conceptualizationofthestudy,interpretationofthedata,draftingthemanuscript.L.M.Fayad:conceptualizationofthestudy,interpretationofthedata,draftingthemanuscript.S.Khan:analysisofthedata.M.A.Bredella:revisingthemanuscriptforintellectualcontent.G.J.Harris:revisingthemanuscriptforintellectualcontent.D.G.Evans:revisingthemanuscriptforintellectualcontent.S.Farschtschi:analysisofthedata,revisingthemanuscriptforintellectualcontent.M.A.Jacobs:analysisofthedata,revisingthemanuscriptforintellectualcontent.A.Chhabra:revisingthemanuscriptforintellectualcontent.J.M.Salamon:revisingthemanuscriptforintellectualcontent.R.Wenzel:analysisofthedata,revisingthemanuscriptforintellectualcontent.V.F.Mautner:revisingthemanuscriptforintellectualcontent.E.Dombi:conceptualizationofthestudy,interpretationofthedata,revisingthemanuscriptforintellectualcontent.W.Cai:interpretationofthedata,revisingthemanuscriptforintellectualcontent.S.R.Plotkin:conceptualizationofthestudy,interpreta-tionofthedata,revisingthemanuscriptforintellectualcontent.J.O.Blakeley:conceptualizationofthestudy,interpretationofthedata,draftingthemanuscript.ACKNOWLEDGMENTTheauthorsthankRhondaJacksonandMonicaR.Sheridanforadministrativesupport.STUDYFUNDINGNotargetedfundingreported.DISCLOSURES.Ahlawatreportsnodisclosuresrelevanttothemanuscript.L.FayadhasreceivedresearchgrantsfromGeneralElectricRadiologyResearchAca-demicFellowshipprogramandSiemensMedicalSystems.M.KhanandM.Bredellareportnodisclosuresrelevanttothemanuscript.G.HarrisreceivesresearchsupportfromChildren’sTumorFoundationandNIH.HealsoservesonthescientificadvisoryboardofFovia,Inc.G.EvansreceivedsupportfromAstraZenecaandhasservedontheboardofFamilialCancerJournal.S.Farschtschireportsnodisclosuresrelevanttothemanuscript.M.JacobsreceivesfundingfromNIH(P50CA103175,5P30CA006973[IRAT],R01CA190299,U01CA140204)andSiemensMedicalSystems(JHU-2012-MR-86-01).A.ChhabrahasreceivedresearchgrantsfromGeneralElectricRadiologyResearchAcademicFellowshippro-gram,SiemensMedicalSolutions,GatewoodFellowshipAward,andInte-graLifeSciences.HealsoservesasaresearchconsultantwithSiemensCADgroup.HereceivesroyaltiesfromWoltersandJaypeePublishers.J.Salamon,R.Wenzel,V.Mautner,andE.Dombireportnodisclosuresrelevanttothemanuscript.W.CaireceivesresearchsupportfromNCI,AmericanCancerSociety,andChildren’sTumorFoundation.HeservesontheeditorialboardsoftheInternationalJournalofIntelligentInformationProcessing,WorldJournalofRadiology,InternationalJournalofRadiology,andAdvancesinModernOncologyResearch.S.PlotkinreceivesresearchsupportfromtheChildren’sTumorFoundation,NIH,andtheDepartmentofDefenseNeurofibromatosisClinicalTrialsConsortium.J.BlakeleyhasreceivedresearchsupportfromGlaxoSmithKline,Sanofi-Aventis,andLilyPharmaceuticals.ShehasconsultedforAbbvie.GotoNeurology.orgforfulldisclosures.ReceivedNovember19,2015.AcceptedinfinalformMay26,2016.REFERENCES1.Toledano-MassiahS,LucianiA,IttiE,etal.Whole-bodydiffusion-weightedimaginginHodgkinlymphomaanddif-fuselargeB-celllymphoma.Radiographics2015;35:747–764.2.PasoglouV,MichouxN,PeetersF,etal.Whole-body3DT1-weightedMRimaginginpatientswithprostatecancer:Neurology87(Suppl1)August16,2016S37ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.feasibilityandevaluationinscreeningformetastaticdis-ease.Radiology2015;275:155–166.3.FriedmanDN,LisE,SklarCA,etal.Whole-bodymag-neticresonanceimaging(WB-MRI)assurveillanceforsubsequentmalignanciesinsurvivorsofhereditaryretino-blastoma:apilotstudy.PediatrBloodCancer2014;61:1440–1444.4.CilibertoM,MaggiF,TregliaG,etal.Comparisonbetweenwhole-bodyMRIandfluorine-18-fluorodeoxyglucosePETorPET/CTinoncology:asystematicreview.RadiolOncol2013;47:206–218.5.SchlemmerHP,SchäferJ,PfannenbergC,etal.Fastwhole-bodyassessmentofmetastaticdiseaseusinganovelmagneticresonanceimagingsystem:initialexperiences.InvestRadiol2005;40:64–71.6.AttariwalaR,PickerW.WholebodyMRI:improvedlesiondetectionandcharacterizationwithdiffusionweightedtechniques.JMagnResonImaging2013;38:253–268.7.MulvihillJJ,ParryDM,ShermanJL,PikusA,Kaiser-KupferMI,EldridgeR.NIHconference:neurofibroma-tosis1(Recklinghausendisease)andneurofibromatosis2(bilateralacousticneurofibromatosis):anupdate.AnnInternMed1990;113:39–52.8.BaserME,FriedmanJM,WallaceAJ,RamsdenRT,JoeH,EvansDG.Evaluationofclinicaldiagnosticcriteriaforneurofibromatosis2.Neurology2002;59:1759–1765.9.MacCollinM,ChioccaEA,EvansDG,etal.Diagnosticcriteriaforschwannomatosis.Neurology2005;64:1838–1845.10.MerkerVL,BredellaMA,CaiW,etal.Relationshipbetweenwhole-bodytumorburden,clinicalphenotype,andqualityoflifeinpatientswithneurofibromatosis.AmJMedGenetA2014;164A:1431–1437.11.NguyenR,JettK,HarrisGJ,CaiW,FriedmanJM,MautnerVF.Benignwholebodytumorvolumeisariskfactormalignantperipheralnervesheathtumorsinneuro-fibromatosistype1.JNeurooncol2014;116:307–313.12.UrbanT,LimR,MerkerVL,etal.Anatomicandmeta-bolicevaluationofperipheralnervesheathtumorsinpa-tientswithneurofibromatosis1usingwhole-bodyMRIand(18)F-FDGPETfusion.ClinNuclMed2014;39:e301–e307.13.FayadLM,BlakeleyJ,PlotkinS,WidemannB,JacobsMA.WholebodyMRIat3Twithquantitativediffusionweightedimagingandcontrast-enhancedsequen-cesforthecharacterizationofperipherallesionsinpatientswithneurofibromatosistype2andschwannomatosis.ISRNRadiol2013;2013:627932.14.DerlinT,TornquistK,MünsterS,etal.Comparativeeffectivenessof18F-FDGPET/CTversuswhole-bodyMRIfordetectionofmalignantperipheralnervesheathtumorsinneurofibromatosistype1.ClinNuclMed2013;38:e19–e25.15.NguyenR,DombiE,WidemannBC,etal.Growthdynamicsofplexiformneurofibromas:aretrospectivecohortstudyof201patientswithneurofibromatosis1.OrphanetJRareDis2012;7:75.16.PlotkinSR,BredellaMA,CaiW,etal.Quantitativeassessmentofwhole-bodytumorburdeninadultpatientswithneurofibromatosis.PLoSOne2012;7:e35711.17.KluweL,NguyenR,VogtJ,etal.InternaltumorburdeninneurofibromatosistypeIpatientswithlargeNF1dele-tions.GenesChromosomesCancer2012;51:447–451.18.NguyenR,KluweL,FuenstererC,KentschM,FriedrichRE,MautnerVF.Plexiformneurofibromasinchildrenwithneurofibromatosistype1:frequencyandassociatedclin-icaldeficits.JPediatr2011;159:652–655.e2.19.CaiW,KassarjianA,BredellaMA,etal.Tumorburdeninpatientswithneurofibromatosistypes1and2andschwan-nomatosis:determinationonwhole-bodyMRimages.Radiology2009;250:665–673.20.VanMeerbeeckSF,VerstraeteKL,JanssensS,MortierG.WholebodyMRimaginginneurofibromatosistype1.EurJRadiol2009;69:236–242.21.MautnerVF,AsuagborFA,DombiE,etal.Assessmentofbenigntumorburdenbywhole-bodyMRIinpatientswithneurofibromatosis1.NeuroOncol2008;10:593–598.22.JaremkoJL,MacMahonPJ,TorrianiM,etal.Whole-bodyMRIinneurofibromatosis:incidentalfindingsandprevalenceofscoliosis.SkeletalRadiol2012;41:917–923.23.KarmazynB,CohenMD,JenningsSG,RobertsonKA.Mar-rowsignalchangesobservedinfollow-upwhole-bodyMRIstudiesinchildrenandyoungadultswithneurofibromatosistype1treatedwithimatinibmesylate(Gleevec)forplexiformneurofibromas.PediatrRadiol2012;42:1218–1222.24.FarschtschiSC,DombiE,WidemannB,FünstererC,MautnerVF.Comparabilityof1.5Tand3.0TMRI-volumetricsinneurofibromatosistype1.Presentedatthe2013NFConference,Monterey,CA.25.BrauckK,ZengeMO,VogtFM,etal.Feasibilityofwhole-bodyMRwithT2-andT1-weightedreal-timesteady-statefreeprecessionsequencesduringcontinuoustablemovementtodepictmetastases.Radiology2008;246:910–916.26.KandaT,IshiiK,KawaguchiH,KitajimaK,TakenakaD.HighsignalintensityinthedentatenucleusandglobuspallidusonunenhancedT1-weightedMRimages:relation-shipwithincreasingcumulativedoseofagadolinium-basedcontrastmaterial.Radiology2014;270:834–841.27.SubhawongTK,DurandDJ,ThawaitGK,JacobsMA,FayadLM.Characterizationofsofttissuemasses:canquantitativediffusionweightedimagingreliablydistin-guishcystsfromsolidmasses?SkeletalRadiol2013;42:1583–1592.28.DemehriS,BelzbergA,BlakeleyJ,FayadLM.ConventionalandfunctionalMRimagingofperipheralnervesheathtu-mors:initialexperience.AJNR2014;35:1615–1620.29.DombiE,Ardern-HolmesSL,Babovic-VuksanovicD,etal.Recommendationsforimagingtumorresponseinneurofi-bromatosisclinicaltrials.Neurology2013;81(21suppl1):S33–S40.30.WidemannBC,BlakeleyJO,DombiE,etal.ConclusionsandfuturedirectionsfortheReiNSInternationalCollab-oration.Neurology2013;81(21suppl1):S41–S44.31.HarrisGJ,PlotkinSR,MacColllinM,etal.Three-dimen-sionalvolumetricsfortrackingvestibularschwannomagrowthinneurofibromatosistypeII.Neurosurgery2008;62:1314–1319.32.HopperKD,KasalesCJ,VanSlykeMA,SchwartzTA,TenHaveTR,JozefiakJA.AnalysisofinterobserverandintraobservervariabilityinCTtumormeasurements.AJRAmJRoentgenol1996;167:851–854.33.DempseyMF,CondonBR,HadleyDM.Measurementoftumor“size”inrecurrentmalignantglioma:1D,2D,or3D?AJNRAmJNeuroradiol2005;26:770–776.34.ErasmusJJ,GladishGW,BroemelingL,etal.Interobserverandintraobservervariabilityinmeasurementofnon-small-S38Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.cellcarcinomalunglesions:implicationsforassessmentoftumorresponse.JClinOncol2003;21:2574–2582.35.ChhabraA,ThakkarRS,AndresisekG,etal.AnatomicMRimagingandfunctionaldiffusiontensorimagingofperipheralnervetumorsandtumorlikeconditions.AJNRAmJNeuroradiol2013;34:802–807.36.SolomonJ,WarrenK,DombiE,PatronasN,WidemannB:Automateddetectionandvolumemeasurementofplexiformneurofibromasinneurofibromatosis1usingmagneticresonanceimaging.ComputMedImagingGraph2004;28:257–265.37.DombiE,SolomonJ,GillespieAJ,etal.NF1plexiformneurofibromagrowthratebyvolumetricMRI:relationshiptoageandbodyweight.Neurology2007;68:643–647.Neurology87(Suppl1)August16,2016S39ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.DOI 10.1212/WNL.00000000000029292016;87;S31-S39 Neurology(cid:160)Shivani Ahlawat, Laura M. Fayad, Muhammad Shayan Khan, et al. schwannomatosisCurrent whole-body MRI applications in the neurofibromatoses: NF1, NF2, andThis information is current as of August 15, 2016ServicesUpdated Information & http://www.neurology.org/content/87/7_Supplement_1/S31.full.htmlincluding high resolution figures, can be found at:Supplementary Material 002929.DC1http://www.neurology.org/content/suppl/2016/08/15/WNL.0000000000Supplementary material can be found at: References ref-list-1http://www.neurology.org/content/87/7_Supplement_1/S31.full.html##This article cites 36 articles, 5 of which you can access for free at: Citations otherarticleshttp://www.neurology.org/content/87/7_Supplement_1/S31.full.html##This article has been cited by 1 HighWire-hosted articles: Subspecialty Collections http://www.neurology.org//cgi/collection/neurofibromatosisNeurofibromatosisfollowing collection(s): This article, along with others on similar topics, appears in the(cid:160) Permissions & Licensing http://www.neurology.org/misc/about.xhtml#permissionsits entirety can be found online at:Information about reproducing this article in parts (figures,tables) or in(cid:160) Reprints http://www.neurology.org/misc/addir.xhtml#reprintsusInformation about ordering reprints can be found online:rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.1951, it is now a weekly with 48 issues per year. Copyright © 2016 American Academy of Neurology. All ® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology(cid:160)